Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus topotecan in second- or third-line small cell lung cancer
ChiCTR2200061709Phase 4Not yet recruiting
- Sponsor
- Fuyang City Cancer Hospital
- Start
- Apr 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib and topotecan in small cell lung cancer (SCLC), sponsored by Fuyang City Cancer Hospital. Primary endpoint: progression-free survival. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
surufatinibtopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2200061709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061709.